Leading the way in innovation for over 55 years, we build greater futures for businesses across multiple industries and 55 countries.
Our expert, committed team put our shared beliefs into action – every day. Together, we combine innovation and collective knowledge to create the extraordinary.
We share news, insights, analysis and research – tailored to your unique interests – to help you deepen your knowledge and impact.
At TCS, we believe exceptional work begins with hiring, celebrating and nurturing the best people — from all walks of life.
Get access to a catalog of the latest news stories from across TCS. Discover our press releases, reports, and company announcements.
TCS ADD ™ Platforms / Article
Hilde Vanaken
Senior Industry Advisor, TCS Life Sciences and Healthcare
Priyanka Sawant
Head, TCS ADD Patient and Site Engagement
You have these already downloaded
We have sent you a copy of the report to your email again.
The COVID-19 pandemic has stalled multiple businesses and processes across the globe including clinical trials since there are critical activities that are carried out on site in-person such as informed consent. The impact is not just seen for new patients but also for existing patients who are required to provide re-consents in accordance with the COVID-19-led changes. To overcome these challenges, an expedited introduction and onboarding of an electronic consenting tool could be a solution. The virtual approach will enable sites to connect with patients without the need for in-person visits. This paper explores digital/virtual approaches to informed consent that could reinstate clinical trials and proceeds to study real-life implementation that Roche has executed to solve its remote consenting challenges for COVID-19 impacted clinical trials.
TCS ADD™ Risk-Based Quality Management Platform
Reimagining Reporting and Visualization During CDM
Advancing Regulatory Intelligence with Conversational, Generative AI
Role of Predictive Model in Operation Risk and Workload Management